My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 139

    1.

    Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers.

    Kirkwood JM, Ernstoff MS, Davis CA, Reiss M, Ferraresi R, Rudnick SA.

    Ann Intern Med. 1985 Jul;103(1):32-6.PMID: 4003987 [PubMed - indexed for MEDLINE]Related articles

    2.

    A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma.

    Ernstoff MS, Trautman T, Davis CA, Reich SD, Witman P, Balser J, Rudnick S, Kirkwood JM.

    J Clin Oncol. 1987 Nov;5(11):1804-10.PMID: 3119786 [PubMed - indexed for MEDLINE]Related articles

    3.

    Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.

    Dillman RO, Soori G, Wiemann MC, Schulof R, Dobbs TW, Ruben RH, DePriest CB, Church C.

    Cancer Biother Radiopharm. 2000 Oct;15(5):487-94.PMID: 11155820 [PubMed - indexed for MEDLINE]Related articles

    4.

    Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic melanoma using two different schedules .

    Legha SS, Papadopoulos NE, Plager C, Ring S, Chawla SP, Evans LM, Benjamin RS.

    J Clin Oncol. 1987 Aug;5(8):1240-6. Erratum in: J Clin Oncol 1987 Nov;5(11):1858. PMID: 3625246 [PubMed - indexed for MEDLINE]Related articles

    5.

    Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma.

    Creagan ET, Ahmann DL, Green SJ, Long HJ, Frytak S, O'Fallon JR, Itri LM.

    J Clin Oncol. 1984 Sep;2(9):1002-5.PMID: 6470751 [PubMed - indexed for MEDLINE]Related articles

    6.

    A Phase II trial of high-dose intravenous interferon alpha-2 in advanced colorectal cancer.

    Silgals RM, Ahlgren JD, Neefe JR, Rothman J, Rudnick S, Galicky FP, Schein PS.

    Cancer. 1984 Nov 15;54(10):2257-61.PMID: 6488145 [PubMed - indexed for MEDLINE]Related articles

    7.

    Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.

    García M, del Muro XG, Tres A, Crespo C, Valladares M, López JJ, Rifà J, Pérez X, Filipovich E, Germà-Lluch JR.

    Melanoma Res. 2006 Aug;16(4):365-70.PMID: 16845333 [PubMed - indexed for MEDLINE]Related articles

    8.

    Phase I study of weekly high-dose human lymphoblastoid interferon.

    Connors JM, Silver HK.

    Cancer Treat Rep. 1984 Sep;68(9):1093-6.PMID: 6478449 [PubMed - indexed for MEDLINE]Related articles

    9.

    Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: implications for the treatment of patients with metastatic melanoma.

    Eton O, Talpaz M, Lee KH, Rothberg JM, Brell JM, Benjamin RS.

    Cancer. 1996 Mar 1;77(5):893-9.PMID: 8608480 [PubMed - indexed for MEDLINE]Related articles

    10.

    Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

    Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH.

    J Clin Oncol. 1996 Jan;14(1):7-17.PMID: 8558223 [PubMed - indexed for MEDLINE]Related articles

    11.

    Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.

    Sosman JA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Weiss GR, Isaacs RE, Margolin KA, Fisher RI, Ernest ML, Mier J, Oleksowicz L, Eckhardt JR, Levitt D, Doroshow JH.

    Clin Cancer Res. 1997 Jan;3(1):39-46.PMID: 9815535 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Phase II trial of lymphoblastoid interferon in metastatic malignant melanoma.

    Goldberg RM, Ayoob M, Silgals R, Ahlgren JD, Neefe JR.

    Cancer Treat Rep. 1985 Jul-Aug;69(7-8):813-6.PMID: 4016791 [PubMed - indexed for MEDLINE]Related articles

    13.

    A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients.

    Sherwin SA, Knost JA, Fein S, Abrams PG, Foon KA, Ochs JJ, Schoenberger C, Maluish AE, Oldham RK.

    JAMA. 1982 Nov 19;248(19):2461-6.PMID: 6752447 [PubMed - indexed for MEDLINE]Related articles

    14.

    [Human recombinant leukocyte interferon alpha-2-A in 22 cases of metastatic malignant melanoma]

    Maral J, Steinberg M, Weil M, Chleq C, Khayat D, Banzet P, Jacquillat C.

    Presse Med. 1987 Jun 6;16(21):1031-4. French. PMID: 2955323 [PubMed - indexed for MEDLINE]Related articles

    15.

    A phase I trial of recombinant interferon-alpha and alpha-difluoromethylornithine in metastatic melanoma.

    Croghan MK, Booth A, Meyskens FL Jr.

    J Biol Response Mod. 1988 Aug;7(4):409-15.PMID: 3139843 [PubMed - indexed for MEDLINE]Related articles

    16.

    Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.

    Phillips GL, Fay JW, Herzig GP, Herzig RH, Weiner RS, Wolff SN, Lazarus HM, Karanes C, Ross WE, Kramer BS.

    Cancer. 1983 Nov 15;52(10):1792-802.PMID: 6354414 [PubMed - indexed for MEDLINE]Related articles

    17.

    A phase I study of rDNA alpha-2b interferon as a 6-week continuous intravenous infusion.

    Smith D, Wagstaff J, Thatcher N, Scarffe H.

    Cancer Chemother Pharmacol. 1987;20(4):327-31.PMID: 3690806 [PubMed - indexed for MEDLINE]Related articles

    18.

    Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.

    Hidalgo OF, Aramendía JM, Alonso G, Foncillas JG, Brugarolas A.

    Rev Med Univ Navarra. 1996 Jul-Sep;40(3):6-12.PMID: 9499820 [PubMed - indexed for MEDLINE]Related articles

    19.

    Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials.

    Ernstoff MS, Fusi S, Kirkwood JM.

    J Biol Response Mod. 1983;2(6):540-7.PMID: 6607324 [PubMed - indexed for MEDLINE]Related articles

    20.

    Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.

    Alatrash G, Hutson TE, Molto L, Richmond A, Nemec C, Mekhail T, Elson P, Tannenbaum C, Olencki T, Finke J, Bukowski RM.

    J Clin Oncol. 2004 Jul 15;22(14):2891-900.PMID: 15254058 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity